Ono Pharmaceutical Announces Establishment of Strategic Alliance Headquarters.Tokyo, Japan, Feb 27, 2007 - (JCN JCN Japan Corporate News
JCN Journal of Cognitive Neuroscience
JCN Journal of Cardiovascular Nursing
JCN Journal of Christian Nursing
JCN Job Control Number
JCN Journal of Child Neurology
JCN joint communications network (US DoD) Newswire) - Ono Pharmaceutical Co., Ltd. announced today that as of March 1, 2007 the Discovery Research Alliance of the Research Headquarters and the International Business of the Development Headquarters will be integrated in a constructive way into one unit to establish a Strategic Alliance Headquarters.
In order to achieve its goal of serving as an R&D-oriented, international pharmaceutical company (global speciality) specializing in defined areas of research based on unique idea of "compound oriented"* that is totally different from other companies in the industry, Ono has striven to discover original and innovative new drugs conforming to global standard in the company's four priority fields: prostaglandins Prostaglandins
Prostaglandins are produced by the body and are responsible for inflammation features, such as swelling, pain, stiffness, redness and warmth. , enzyme inhibitors Enzyme inhibitors are molecules that bind to enzymes and decrease their activity. Since blocking an enzyme's activity can kill a pathogen or correct a metabolic imbalance, many drugs are enzyme inhibitors. They are also used as herbicides and pesticides. , neuroscience neu·ro·sci·ence
Any of the sciences, such as neuroanatomy and neurobiology, that deal with the nervous system.
the embryology, anatomy, physiology, biochemistry and pharmacology of the nervous system. , and intracellular intracellular /in·tra·cel·lu·lar/ (-sel´u-ler) within a cell or cells.
Occurring or situated within a cell or cells. signaling, where we can fully benefit from the technologies we have accumulated in the past, and now adding genomic drug discovery on top of these four areas.
Discovery Research Alliance, newly created in April 2005, is aggressively seeking and promoting alliances with bioventure companies and research institutions within and outside Japan in order to strengthen discovery research capability by gaining access to cutting-edge technologies and discovery seeds. This newly established section has already made remarkable achievements as launching collaborative drug discovery programs relating to relating to relate prep → concernant
relating to relate prep → bezüglich +gen, mit Bezug auf +acc inhibitors of kinase kinase /ki·nase/ (ki´nas)
1. a subclass of the transferases, comprising the enzymes that catalyze the transfer of a high-energy group from a donor (usually ATP) to an acceptor.
2. , one of the intracellular enzymes that is involved in various diseases, with two U.S. bioventure companies.
Further to that, Ono has made efforts to strengthen our development pipeline by acquiring in-licensing products aggressively. This time, International Business of Development Headquarters that has been in charge of inand out-licensing activities and Discovery Research Alliance of Research Headquarters that has pursued search and alliances of discovery seeds will be integrated in a constructive way into one unit as establishing Strategic Alliance Headquarters in order to further strengthen discovery research capability and expansion of development pipeline by promoting strategic alliances. Strategic Alliance Headquarters is anticipated to take an important role in improving overall research and development capability while closely coordinating with Research Headquarters and Development Headquarters.
Discovery Research Alliance
Discovery Research Alliance is aggressively seeking and promoting collaborative research and alliances with bioventure companies and research institutions such as universities mainly in the U.S. and Europe in order to strengthen discovery research capability and development pipeline by gaining access to discovery seeds and cutting-edge technologies.
The section is aiming at 10 new discovery alliances to be acquired from bioventure companies and new research alliances to be collaborated with 20 to 30 universities within and outside Japan during the next 5 years.
The focus had been on in-licensing new drug candidates of later stages of development at Business Development, but in future the section will also direct its effort into acquiring early stage development compounds (preclinical preclinical /pre·clin·i·cal/ (-klin´i-k'l) before a disease becomes clinically recognizable.
1. and Phase I stage) in order to further expand our development pipeline.
The section is aiming at in-licensing 10 new compounds during the next 5 years.
Licensing and Business Research
Licensing and Business Research section will perform information search and collection for business alliances and promote contract negotiation by obtaining cross-sectional cooperation from other headquarters on demand.
* Compound oriented: It is an idea that development and commercialization compounds generated from inquisitive in·quis·i·tive
1. Inclined to investigate; eager for knowledge.
2. Unduly curious and inquiring. See Synonyms at curious. mind of scientists towards newly discovered vital phenomena and unique theories are pursued without identifying specific disease areas.
About Ono Pharmaceutical Co Ltd.
Ono Pharmaceutical Co Ltd.(TSE See Tokyo Stock Exchange.
1. See Tokyo Stock Exchange (TSE).
2. See Toronto Stock Exchange (TSE). : 4528) Manufacturer and marketer of prescription pharmaceutical products, OTC OTC
See over-the-counter market (OTC). drugs. Operations are carried out through the following sectors: Pharmaceuticals (Digestive agents, Circulatory circulatory /cir·cu·la·to·ry/ (ser´ku-lah-tor?e)
1. pertaining to circulation, particularly that of the blood.
2. containing blood.
1. & respiratory agents, Vitamins & metabolic agents, Diagnostics reagents); Services and Other operations (Printing, Publishing, Distribution, Insurance agnecy, Transportation). Pharmaceuticals accounted for 100% of fiscal 2001 revenues; services and other operations, nominal.
Source: Ono Pharmaceutical Co Ltd.
Ono Pharmaceutical Co., Ltd. Public Relations Phone: +81-6-6263-5670 Fax: +81-6-6263-2950
Copyright [c] 2007 JCN Newswire. All rights reserved. A division of Japan Corporate News Network K.K.